Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Vibegron

FDA-approved product (tablet, oral), marketed as Gemtesa.

Registered studies
16
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Vibegron
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Overactive bladder
  • Polyuria
  • Urgency urinary incontinence
  • Urinary incontinence

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Drugs for urinary frequency and incontinence
FDA pharmacologic class
beta3-Adrenergic Agonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli50.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis51.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

16registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Vibegron in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-10.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Vibegron with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Vibegron for ENergy Thinking and Resilience in Aging

    NCT06987383 · start 2026-10

    Registered record
    Registry ID
    NCT06987383
    Conditions
    Obesity
    Interventions
    Vibegron; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-10
    Completion
    2028-07
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObesity
    InterventionVibegron; Placebo
    PhasePhase 3
    Registry statusNot yet recruiting

  • Role of Combination Therapy in Women With Refractory Overactive Bladder

    NCT06438861 · start 2025-01-01

    Registered record
    Registry ID
    NCT06438861
    Conditions
    Overactive Bladder Syndrome
    Interventions
    Vibegron 75mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2025-01-01
    Completion
    2025-12-31
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOveractive Bladder Syndrome
    InterventionVibegron 75mg; Placebo
    PhaseNot applicable
    Registry statusWithdrawn

  • Efficacy of Mirabegron for Treatment of Non-monosymptomatic Nocturnal Enuresis in Children

    NCT07398261 · start 2023-08-28

    Registered record
    Registry ID
    NCT07398261
    Conditions
    Treatment of Non-monosymptomatic Nocturnal Enuresis
    Interventions
    Mirabegron 25 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2023-08-28
    Completion
    2026-11-01
    Enrolment
    151

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTreatment of Non-monosymptomatic Nocturnal Enuresis
    InterventionMirabegron 25 MG
    PhasePhase 3
    Registry statusActive not recruiting

  • Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence

    NCT05806164 · start 2023-06-06

    Registered record
    Registry ID
    NCT05806164
    Conditions
    Urgency Urinary Incontinence
    Interventions
    Beta3-Agonists, Adrenergic [Mirabegron/Vibegron]; OnabotulinumtoxinA 100 UNT [Botox]
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2023-06-06
    Completion
    2030-08-01
    Enrolment
    432

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrgency Urinary Incontinence
    InterventionBeta3-Agonists, Adrenergic [Mirabegron/Vibegron]; OnabotulinumtoxinA 100 UNT [Botox]
    PhasePhase 4
    Registry statusActive not recruiting

  • Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC

    NCT05491525 · start 2022-10-12

    Registered record
    Registry ID
    NCT05491525
    Conditions
    Neurogenic Detrusor Overactivity
    Interventions
    Vibegron
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2022-10-12
    Completion
    2030-09
    Enrolment
    71

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeurogenic Detrusor Overactivity
    InterventionVibegron
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)

    NCT05067478 · start 2021-10-28

    Registered record
    Registry ID
    NCT05067478
    Conditions
    Overactive Bladder
    Interventions
    Vibegron
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-10-28
    Completion
    2024-07-26
    Enrolment
    403

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOveractive Bladder
    InterventionVibegron
    PhaseNot recorded
    Registry statusCompleted

  • To Evaluate the Efficacy and Safety of JLP-2002 on Symptoms of Overactive Bladder

    NCT04917315 · start 2020-05-21

    Registered record
    Registry ID
    NCT04917315
    Conditions
    Overactive Bladder
    Interventions
    JLP-2002 A mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-05-21
    Completion
    2021-08-18
    Enrolment
    210

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOveractive Bladder
    InterventionJLP-2002 A mg; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia

    NCT04103450 · start 2019-09-19

    Registered record
    Registry ID
    NCT04103450
    Conditions
    Overactive Bladder
    Interventions
    Vibegron
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-09-19
    Completion
    2022-07-29
    Enrolment
    276

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOveractive Bladder
    InterventionVibegron
    PhasePhase 3
    Registry statusCompleted

  • Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)

    NCT03902080 · start 2019-03-26

    Registered record
    Registry ID
    NCT03902080
    Conditions
    Overactive Bladder
    Interventions
    Vibegron; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-03-26
    Completion
    2023-06-15
    Enrolment
    1,105

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOveractive Bladder
    InterventionVibegron; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome

    NCT03806127 · start 2018-12-31

    Registered record
    Registry ID
    NCT03806127
    Conditions
    Irritable Bowel Syndrome
    Interventions
    Vibegron; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-12-31
    Completion
    2020-10-06
    Enrolment
    222

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIrritable Bowel Syndrome
    InterventionVibegron; Placebo
    PhasePhase 2
    Registry statusCompleted

  • An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).

    NCT03583372 · start 2018-06-14

    Registered record
    Registry ID
    NCT03583372
    Conditions
    Overactive Bladder
    Interventions
    Vibegron; placebos; Tolterodine Tartrate ER
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-06-14
    Completion
    2019-07-25
    Enrolment
    506

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOveractive Bladder
    InterventionVibegron; placebos; Tolterodine Tartrate ER
    PhasePhase 3
    Registry statusCompleted

  • A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)

    NCT03492281 · start 2018-03-26

    Registered record
    Registry ID
    NCT03492281
    Conditions
    Overactive Bladder
    Interventions
    vibegron; Vibegron placebo; Tolterodine Tartrate ER; Tolterodine placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-03-26
    Completion
    2019-02-04
    Enrolment
    1,530

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOveractive Bladder
    Interventionvibegron; Vibegron placebo; Tolterodine Tartrate ER; Tolterodine placebo
    PhasePhase 3
    Registry statusCompleted

  • A Single-Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Adults With Hepatic Insufficiency (MK-4618-013)

    NCT01737684 · start 2013-01-15

    Registered record
    Registry ID
    NCT01737684
    Conditions
    Overactive Bladder
    Interventions
    Vibegron
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-01-15
    Completion
    2013-06-14
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOveractive Bladder
    InterventionVibegron
    PhasePhase 1
    Registry statusCompleted

  • A Single Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Participants With Renal Insufficiency (MK-4618-014)

    NCT01628042 · start 2012-07-16

    Registered record
    Registry ID
    NCT01628042
    Conditions
    Overactive Bladder
    Interventions
    Vibegron 100 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-07-16
    Completion
    2013-01-25
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOveractive Bladder
    InterventionVibegron 100 mg
    PhasePhase 1
    Registry statusCompleted

  • A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004)

    NCT01500382 · start 2012-02-27

    Registered record
    Registry ID
    NCT01500382
    Conditions
    Overactive Bladder; Overactive Urinary Bladder
    Interventions
    Vibegron; Tolterodine ER; Placebo (vibegron); Placebo (tolterodine ER); Prophylactic Antibiotic
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2012-02-27
    Completion
    2013-01-02
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOveractive Bladder; Overactive Urinary Bladder
    InterventionVibegron; Tolterodine ER; Placebo (vibegron); Placebo (tolterodine ER) +1 more
    PhasePhase 1
    Registry statusTerminated